{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T13:24:04Z","timestamp":1789219444582,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T00:00:00Z","timestamp":1764460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG062840"],"award-info":[{"award-number":["R01AG062840"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG085724"],"award-info":[{"award-number":["R01AG085724"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics: X"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ijpx.2025.100459","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T08:02:59Z","timestamp":1764662579000},"page":"100459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Longitudinal pharmacokinetic and safety studies of an antibody-erythropoietin fusion protein for Alzheimer's disease"],"prefix":"10.1016","volume":"10","author":[{"given":"Rudy","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devaraj V.","family":"Chandrashekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Chuli","family":"Roules","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataraj","family":"Jagadeesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adenike","family":"Oyegbesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayk","family":"Davtyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachita K.","family":"Sumbria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ijpx.2025.100459_bb0005","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3233\/JAD-141389","article-title":"Memory improvement in the A\u03b2PP\/PS1 mouse model of familial Alzheimer\u2019s disease induced by carbamylated-erythropoietin is accompanied by modulation of synaptic genes","volume":"45","author":"Armand-Ug\u00f3n","year":"2015","journal-title":"J. Alzheimer\u2019s Dis"},{"issue":"2","key":"10.1016\/j.ijpx.2025.100459_bb0010","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20131660","article-title":"Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants","volume":"211","author":"Bien-Ly","year":"2014","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.ijpx.2025.100459_bb0015","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1038\/s41598-025-89051-8","article-title":"Longitudinal characterization reveals behavioral impairments in aged APP knock in mouse models","volume":"15","author":"Blackmer-Raynolds","year":"2025","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ijpx.2025.100459_bb0020","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1124\/jpet.109.165092","article-title":"Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse","volume":"333","author":"Boado","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/j.ijpx.2025.100459_bb0025","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrn1687","article-title":"Emerging biological roles for erythropoietin in the nervous system","volume":"6","author":"Brines","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"issue":"9","key":"10.1016\/j.ijpx.2025.100459_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12090852","article-title":"Acute and chronic dosing of a high-affinity rat\/mouse chimeric transferrin receptor antibody in mice","volume":"12","author":"Castellanos","year":"2020","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.ijpx.2025.100459_bb0035","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1021\/acs.molpharmaceut.7b00200","article-title":"Blood-brain barrier penetrating biologic TNF-alpha inhibitor for Alzheimer\u2019s disease","volume":"14","author":"Chang","year":"2017","journal-title":"Mol. Pharm."},{"issue":"11","key":"10.1016\/j.ijpx.2025.100459_bb0040","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1021\/acs.molpharmaceut.8b00594","article-title":"Brain penetrating bifunctional erythropoietin-transferrin receptor antibody fusion protein for Alzheimer\u2019s disease","volume":"15","author":"Chang","year":"2018","journal-title":"Mol. Pharm."},{"issue":"183","key":"10.1016\/j.ijpx.2025.100459_bb0045","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005338","article-title":"Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier","volume":"5","author":"Couch","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ijpx.2025.100459_bb0050","first-page":"1","article-title":"A simple role for BDNF in learning and memory?","volume":"3","author":"Cunha","year":"2010","journal-title":"Front. Mol. Neurosci."},{"issue":"1","key":"10.1016\/j.ijpx.2025.100459_bb0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer\u2019s disease","volume":"14","author":"DeTure","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ijpx.2025.100459_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.930402","article-title":"Modulation of hepatic amyloid precursor protein and lipoprotein receptor-related protein 1 by chronic alcohol intake: potential link between liver steatosis and amyloid-\u03b2","volume":"13","author":"Garcia","year":"2022","journal-title":"Front. Physiol."},{"issue":"7","key":"10.1016\/j.ijpx.2025.100459_bb0065","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.ymthe.2021.03.019","article-title":"Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: a phase 2 trial in Brazil","volume":"29","author":"Giugliani","year":"2021","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.ijpx.2025.100459_bb0070","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13195-023-01236-3","article-title":"Long-term effects of immunotherapy with a brain penetrating Abeta antibody in a mouse model of Alzheimer\u2019s disease","volume":"15","author":"Gustavsson","year":"2023","journal-title":"Alzheimer\u2019s Res. Ther."},{"issue":"10","key":"10.1016\/j.ijpx.2025.100459_bb0075","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-\u03b2 pathway in Alzheimer\u2019s disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.ijpx.2025.100459_bb0080","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.dadm.2015.01.005","article-title":"Plasma BDNF levels associate with Pittsburgh compound B binding in the brain","volume":"1","author":"Hwang","year":"2015","journal-title":"Alzheimers Dement (Amst)."},{"issue":"1","key":"10.1016\/j.ijpx.2025.100459_bb0085","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s12967-024-05008-x","article-title":"Modulation of hippocampal protein expression by a brain penetrant biologic TNF-\u03b1 inhibitor in the 3xTg Alzheimer\u2019s disease mice","volume":"22","author":"Jagadeesan","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ijpx.2025.100459_bb0090","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jneumeth.2014.02.001","article-title":"Burrowing and nest building behavior as indicators of well-being in mice","volume":"234","author":"Jirkof","year":"2014","journal-title":"J. Neurosci. Methods"},{"issue":"1","key":"10.1016\/j.ijpx.2025.100459_bb0095","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1038\/s41598-018-22081-7","article-title":"A small molecule inhibitor of nicotinamide N-methyltransferase for the treatment of metabolic disorders","volume":"8","author":"Kannt","year":"2018","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.ijpx.2025.100459_bb0100","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.biopsych.2007.01.002","article-title":"Correlation between serum brain-derived neurotrophic factor level and an in vivo marker of cortical integrity","volume":"62","author":"Lang","year":"2007","journal-title":"Biol. Psychiatry"},{"issue":"10","key":"10.1016\/j.ijpx.2025.100459_bb0105","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1517\/13543784.2010.517954","article-title":"Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma!","volume":"19","author":"Lapchak","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.ijpx.2025.100459_bb0110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3233\/JAD-2008-15112","article-title":"Differential changes in synaptic proteins in the Alzheimer frontal cortex with marked increase in PSD-95 postsynaptic protein","volume":"15","author":"Leuba","year":"2008","journal-title":"J. Alzheimer\u2019s Dis"},{"issue":"3","key":"10.1016\/j.ijpx.2025.100459_bb0115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.nbd.2009.08.007","article-title":"An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer\u2019s disease","volume":"36","author":"Lord","year":"2009","journal-title":"Neurobiol. Dis."},{"issue":"Pt 1","key":"10.1016\/j.ijpx.2025.100459_bb0120","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1113\/jphysiol.2006.122689","article-title":"Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume","volume":"578","author":"Lundby","year":"2007","journal-title":"J. Physiol."},{"issue":"1","key":"10.1016\/j.ijpx.2025.100459_bb0125","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s12974-021-02332-7","article-title":"Biologic TNF-alpha inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy","volume":"18","author":"Ou","year":"2021","journal-title":"J. Neuroinflammation"},{"issue":"10","key":"10.1016\/j.ijpx.2025.100459_bb0130","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.3390\/pharmaceutics14102200","article-title":"Efficacy and safety of a brain-penetrant biologic TNF-\u03b1 inhibitor in aged APP\/PS1 mice","volume":"14","author":"Ou","year":"2022","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.ijpx.2025.100459_bb0135","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1021\/acs.molpharmaceut.8b00730","article-title":"Blood-brain barrier transport, plasma pharmacokinetics, and neuropathology following chronic treatment of the rhesus monkey with a brain penetrating humanized monoclonal antibody against the human transferrin receptor","volume":"15","author":"Pardridge","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpx.2025.100459_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2023.114707","article-title":"Apathy-like behaviour in tau mouse models of Alzheimer\u2019s disease and frontotemporal dementia","volume":"456","author":"Robinson","year":"2024","journal-title":"Behav. Brain Res."},{"issue":"6","key":"10.1016\/j.ijpx.2025.100459_bb0145","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"issue":"8","key":"10.1016\/j.ijpx.2025.100459_bb0150","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1073\/pnas.94.8.4109","article-title":"Disaggregation of Alzheimer beta-amyloid by site-directed mAb","volume":"94","author":"Solomon","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.ijpx.2025.100459_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186046","article-title":"Massive immune response against IVIg interferes with response against other antigens in mice: a new mode of action?","volume":"12","author":"Sorde","year":"2017","journal-title":"PLoS One"},{"issue":"5\u20136","key":"10.1016\/j.ijpx.2025.100459_bb0160","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/10408363.2010.550461","article-title":"Biological and clinical aspects of soluble transferrin receptor","volume":"47","author":"Speeckaert","year":"2010","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"4","key":"10.1016\/j.ijpx.2025.100459_bb0165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1208\/s12248-022-00728-8","article-title":"Comparison of titer and signal to noise (S\/N) for determination of anti-drug antibody magnitude using clinical data from an industry consortium","volume":"24","author":"Starcevic Manning","year":"2022","journal-title":"AAPS J."},{"issue":"3","key":"10.1016\/j.ijpx.2025.100459_bb0170","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jnr.22227","volume":"88","author":"Sultana","year":"2010","journal-title":"J. Neurosci. Res."},{"issue":"1","key":"10.1016\/j.ijpx.2025.100459_bb0175","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12017-019-08524-y","article-title":"The promises and challenges of erythropoietin for treatment of Alzheimer\u2019s disease","volume":"21","author":"Sun","year":"2019","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.ijpx.2025.100459_bb0180","first-page":"627","article-title":"Hematologic safety of chronic brain-penetrating erythropoietin dosing in APP\/PS1 mice","volume":"5","author":"Sun","year":"2019","journal-title":"Alzheimers Dement."},{"issue":"8","key":"10.1016\/j.ijpx.2025.100459_bb0185","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1021\/acs.molpharmaceut.9b00369","article-title":"Plasma pharmacokinetics of high-affinity transferrin receptor antibody-erythropoietin fusion protein is a function of effector attenuation in mice","volume":"16","author":"Sun","year":"2019","journal-title":"Mol. Pharm."},{"issue":"Pt B","key":"10.1016\/j.ijpx.2025.100459_bb0190","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.nbd.2016.05.008","article-title":"The role of BDNF in Alzheimer\u2019s disease","volume":"97","author":"Tanila","year":"2017","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.ijpx.2025.100459_bb0195","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3233\/JAD-140741","article-title":"The murine version of BAN2401 (mAb158) selectively reduces amyloid-\u03b2 protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice","volume":"43","author":"Tucker","year":"2015","journal-title":"J. Alzheimer\u2019s Dis"},{"issue":"2","key":"10.1016\/j.ijpx.2025.100459_bb0200","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1471-4159.2005.03033.x","article-title":"Erythropoietin protects primary hippocampal neurons increasing the expression of brain-derived neurotrophic factor","volume":"93","author":"Viviani","year":"2005","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.ijpx.2025.100459_bb0205","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13024-022-00547-7","article-title":"Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia","volume":"17","author":"Xia","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ijpx.2025.100459_bb0210","article-title":"Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II","volume":"27","author":"Yamamoto","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ijpx.2025.100459_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.mex.2021.101584","article-title":"The concentration of brain homogenates with the Amicon Ultra Centrifugal filters","volume":"8","author":"Yang","year":"2021","journal-title":"MethodsX"},{"issue":"3","key":"10.1016\/j.ijpx.2025.100459_bb0220","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s44319-024-00090-0","article-title":"Hyperfunction of post-synaptic density protein 95 promotes seizure response in early-stage abeta pathology","volume":"25","author":"Yook","year":"2024","journal-title":"EMBO Rep."},{"issue":"261","key":"10.1016\/j.ijpx.2025.100459_bb0225","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009835","article-title":"Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates","volume":"6","author":"Yu","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.ijpx.2025.100459_bb0230","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.ijpx.2025.100459_bb0235","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1021\/mp1001763","article-title":"Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse","volume":"7","author":"Zhou","year":"2010","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.ijpx.2025.100459_bb0240","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1124\/dmd.111.038349","article-title":"Chronic dosing of mice with a transferrin receptor monoclonal antibody-glial-derived neurotrophic factor fusion protein","volume":"39","author":"Zhou","year":"2011","journal-title":"Drug Metab. Dispos."}],"container-title":["International Journal of Pharmaceutics: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156725001446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156725001446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T14:48:26Z","timestamp":1768402106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590156725001446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":48,"alternative-id":["S2590156725001446"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpx.2025.100459","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6874797\/v1","asserted-by":"object"}]},"ISSN":["2590-1567"],"issn-type":[{"value":"2590-1567","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal pharmacokinetic and safety studies of an antibody-erythropoietin fusion protein for Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpx.2025.100459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100459"}}